Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity
Siân R. Kitcher, … , Guy P. Richardson, Corné J. Kros
Siân R. Kitcher, … , Guy P. Richardson, Corné J. Kros
Published August 8, 2019
Citation Information: JCI Insight. 2019;4(15):e126764. https://doi.org/10.1172/jci.insight.126764.
View: Text | PDF
Research Article Neuroscience Therapeutics

ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity

  • Text
  • PDF
Abstract

Aminoglycoside (AG) antibiotics are widely used to prevent life-threatening infections, and cisplatin is used in the treatment of various cancers, but both are ototoxic and result in loss of sensory hair cells from the inner ear. ORC-13661 is a new drug that was derived from PROTO-1, a compound first identified as protective in a large-scale screen utilizing hair cells in the lateral line organs of zebrafish larvae. Here, we demonstrate, in zebrafish larvae and in mouse cochlear cultures, that ORC-13661 provides robust protection of hair cells against both ototoxins, the AGs and cisplatin. ORC-13661 also prevents both hearing loss in a dose-dependent manner in rats treated with amikacin and the loading of neomycin-Texas Red into lateral line hair cells. In addition, patch-clamp recordings in mouse cochlear cultures reveal that ORC-13661 is a high-affinity permeant blocker of the mechanoelectrical transducer (MET) channel in outer hair cells, suggesting that it may reduce the toxicity of AGs by directly competing for entry at the level of the MET channel and of cisplatin by a MET-dependent mechanism. ORC-13661 is therefore a promising and versatile protectant that reversibly blocks the hair cell MET channel and operates across multiple species and toxins.

Authors

Siân R. Kitcher, Nerissa K. Kirkwood, Esra D. Camci, Patricia Wu, Robin M. Gibson, Van A. Redila, Roberto Ogelman, Julian A. Simon, Edwin W. Rubel, David W. Raible, Guy P. Richardson, Corné J. Kros

×

Figure 2

ORC-13661 protects mouse outer hair cells from gentamicin damage.

Options: View larger image (or click on image) Download as PowerPoint
ORC-13661 protects mouse outer hair cells from gentamicin damage.
(A–C) ...
(A–C) One-day-old mouse cochlear cultures prepared from P2 mice were transferred into low-serum medium (LSM) and grown for an additional 48 hours in LSM alone, LSM containing 5 μM gentamicin, or LSM containing 5 μM gentamicin in the presence of 20 μM ORC-13661. Hair cell loss was not seen in LSM alone (A) whereas substantial outer hair cell (OHC) loss was seen in the presence of 5 μM gentamicin (B). Coincubation with 20 μM ORC-13661 offered protection against the gentamicin-induced damage (C). I, inner hair cell row; O1, OHC row 1; O2, OHC row 2; O3, OHC row 3. (D) Dose-response relationship for ORC-13661 protection against 5 μM gentamicin. Concentrations of ORC-13661 ≤5 μM offered no protection, 10 μM offered partial protection, and ≥20 μM offered full protection. Results are shown for the basal ROI. OHCs were counted in a 221-μm length of the organ of Corti from each cochlea. Number of cochleae used were as follows: control, 12; 5 μM gentamicin, 14; 5 μM gentamicin + [ORC-13661]: 1 μM, 4; 3 μM, 6; 5 μM, 4; 10 μM, 14; 20 μM, 11; 30 μM, 5. For statistical analysis 1-way ANOVA was used; ***P ≤ 0.001. Error bars represent SEM. Scale bar: 20 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts